Virax Biolabs Group Limited announced the immediate exercise of preferred investment options to purchase 548,000 ordinary shares at a reduced price of $6.00 per share, down from $10.00. This move is expected to raise approximately $3.3 million before fees, with proceeds intended for general corporate purposes. The company also issued new unregistered warrants to purchase additional shares, contingent on shareholder approval to increase authorized shares. The offering is set to close around July 10, 2026, supporting Virax's ongoing development of immune profiling and diagnostic technologies.
Vishay Intertechnology introduced the VOMHA43A, a high-speed automotive optocoupler in a narrow 3.6 mm SOP-5 package that saves PCB space while enhancing signal quality. It offers industry-leading common mode transient immunity of 40 kV/µS and a peak...
Travelzoo announced three new exclusive travel deals for its U.S. Club Members: a $599 all-inclusive adults-only getaway in Tulum with flights and room upgrades, a $1399 Tuscan cooking experience with a Michelin-star chef including wine tasting and g...
Japan's government revised its economic blueprint to explicitly affirm the Bank of Japan's independence after an earlier draft linked monetary policy to government growth targets, which spooked investors. The initial plan had urged the BOJ to align w...
New Jersey American Water has started the 2026 Flow Forward Summer Camp in Camden, offering high school students from Free All Minds and Women of the Dream a three-day program focused on career exploration in the water industry. The camp includes han...
The Alerian MLP ETF (AMLP) is recommended as a buy due to its stable, high dividend yield of 7.5% and exposure to North American energy infrastructure. It benefits from long-term contracts that ensure steady earnings and avoids complex tax issues lik...
